Matthew Hatton, MSc, MBChB, MRCP, FRCP, FRCR, University of Sheffield, Sheffield, UK, outlines the role of the National Cancer Research Institute (NCRI) Lung Cancer Study Group in the management and maintenance of clinical trials in the UK. He highlights the focus on testing combinations of new drugs and radiotherapy, palliative radiotherapy, and the living with and beyond cancer initiative. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.